摘要
早产儿视网膜病变(Retinopathy of Prematurity, ROP)是一种发育性血管增殖性病变,发生于视网膜血管化不完全的早产儿的视网膜,是儿童严重视力障碍的重要原因。血管内皮生长因子(VEGF)是眼部病理性新生血管形成和血管通透性的重要介质,以VEGF为靶点的玻璃体腔内注射治疗的广泛使用使儿童玻璃体视网膜疾病的治疗发生了革命性的变化,是眼科和儿科基础及临床研究关注热点。本文就ROP抗VEGF药物治疗研究进展及存在问题做一综述。
Retinopathy of prematurity (ROP) is a developmental angioproliferative lesion that occurs in the retina of premature infants with incomplete retinal vascularization and is an important cause of severe visual impairment in children. Vascular endothelial growth factor (VEGF) is an important mediator of ocular pathological neovascularization and vascular permeability, and the widespread use of intravitreal injection therapy targeting VEGF has revolutionized the treatment of children’s vitreoretinal diseases, and is a focus of basic and clinical research in ophthalmology and pediatrics. This article reviews the research progress and existing problems of ROP anti-VEGF drug treatment.
出处
《临床医学进展》
2023年第5期7128-7134,共7页
Advances in Clinical Medicine
